DFTX — DEFINIUM THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying DFTX?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their DFTX position last quarter, 3 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Contraction regime).
- +3 tracked investors added or increased positions last quarter (Paul Tudor Jones, Stanley Druckenmiller, Steve Cohen)
- +5 tracked investors reported holding DFTX at their latest filing
- +Macro Health is 55/100 in a Contraction regime — historically acceptable for this sectorsource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/17/2026.
About DEFINIUM THERAPEUTICS INC (DFTX)
DEFINIUM THERAPEUTICS INC (DFTX) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $106M. Across recent filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in DFTX
How many top investors track DFTX
A small number of top investors own this.
DFTX Ownership Composition
How DEFINIUM THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant89.6%
- Macro10.4%
Tracked investors currently reporting DFTX
- Ken GriffinJun 30, 2026Citadel AdvisorsShares2.3MValue$106.4M% Portfolio0.01%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares484KValue$22.8M% Portfolio0.03%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares376.1KValue$17.7M% Portfolio0.01%
- Stanley DruckenmillerJun 30, 2026Duquesne Family OfficeShares356.6KValue$16.8M% Portfolio0.32%
- Paul Tudor JonesJun 30, 2026Tudor Investment CorpShares4.5KValue$211.7K% Portfolio0.00%
Recent activity
- New$3.3MMay 15, 2026
- Increased$22.8M(175.79%)Aug 14, 2026
- $211.7KAug 14, 2026
- $16.8MAug 14, 2026
Frequently asked questions
- How many institutional investors hold DFTX?
- 5 tracked institutional investors disclosed a position in DFTX (DEFINIUM THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of DFTX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in DFTX, valued at $106M.
- Did institutional ownership of DFTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 0 fully exited DFTX.
- Where does this DFTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.